Viridian Therapeutics, Inc.\DE (VRDN) financials

Viridian Therapeutics, Inc.\DE (VRDN) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Viridian Therapeutics, Inc.\DE reported revenue of $71M, net income of -$343M and free cash flow of -$277M.

Revenue (fiscal 2025)

$71M

Net income (fiscal 2025)

-$343M

Free cash flow (fiscal 2025)

-$277M

Viridian Therapeutics, Inc.\DE files with the U.S. Securities and Exchange Commission under CIK 0001590750, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.